Comprehensive Methylome Map of Myeloid and Lymphoid Commitment from Hematopoietic Proenitors

• US 20130281304A1
• Filed: 08/12/2011
• Published: 10/24/2013
• Est. Priority Date: 08/13/2010
• Status: Abandoned Application

• Current Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford University)
• Original Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford University)
• Inventors: Feinberg, Andrew P., Weissman, Irving L.
• Application Number:
  US13/814,460
• Publication Number:
  US 20130281304A1
• Time in Patent Office: Days
• US Class Current: 506/2
• CPC Class Codes: C12Q 1/6881 for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• CPC Class Codes: C12Q 2600/154 Methylation markers

Abstract

Provided herein are differentially methylated regions (DMRs) of multipotent progenitor cells (MPPs) and oligopotent progenitor cells and methods of use thereof. The invention provides methods for detecting and analyzing alterations in the methylation status of DMRs in such progenitor cells as well as methods for differentiating such cells.

Claims

1. A method of identifying the differentiation potential of a cell comprising:

comparing the methylation status of one or more nucleic acid sequences of a cell to a known methylation status of the one or more nucleic acid sequences of a reference progenitor cell, wherein a similarity or a difference in methylation status between the cell and the reference cell is indicative of the differentiation potential of the cell.

2. The method of claim 1, with the proviso that the one or more nucleic acid sequences are outside of a promoter region of a gene and outside of a CpG island, and wherein the nucleic acid sequences are up to about 2 kb in distance from a CpG island.

3. The method of claim 2, wherein the one or more nucleic acid sequences are within a gene.

4. The method of claim 2, wherein the one or more nucleic acid sequences are upstream or downstream of a gene.

5. The method of claim 1, wherein the one or more nucleic acid sequences are selected from the group consisting of differentially methylated region (DMR) sequences as set forth in Tables 2a to 2h, FIGS. 1, 3, 5, 8, 9, 10 and any combination thereof.

6. The method of claim 1, wherein the methylation status is performed by one or more techniques selected from the group consisting of a nucleic acid amplification, polymerase chain reaction (PCR), methylation specific PCR, bisulfite pyrosequencing, single-strand conformation polymorphism (SSCP) analysis, restriction analysis, microarray technology, and proteomics.

7. The method of claim 1, wherein the reference progenitor cell is a multipotent progenitor (MPP) cell or an oligopotent progenitor.

8. The method of claim 7, wherein the reference progenitor cell is an oligopotent progenitor selected from a common lymphoid progenitor (CLP) or a common myeloid progenitor (CMP).

9. The method of claim 1, wherein the reference progenitor cell is a granulocyte/macrophage progenitor (GMP), a thymocyte progenitor, or a megakaryocyte-erythrocyte progenitor (MEP).

55. A method of generating a cell bank comprising:

(a) identifying the differentiation potential of a plurality of cells using the method of claim 1; and

(b) sorting the cells of (a) by differentiation potential.

56. The method of claim 55, wherein differentiation potential is cell lineage specific.

57. A cell bank produced by the method of claim 55.

10. A method of modifying the lineage restriction of a partially or terminally differentiated myeloid or lymphoid cell comprising contacting a partially or terminally differentiated myeloid or lymphoid cell with an agent which alters regulation of the expression or expression product of a gene known to be associated with the differentiation potential of the cell, thereby modifying the lineage restriction of the cell.

11. The method of claim 10, wherein the agent alters regulation of the expression or expression product of a gene set forth in Tables 2a to 2h, Tables 3a to 3h, FIGS. 1, 3, 5, 8, 9, 10 and any combination thereof.

12. The method of claim 10, wherein the agent is a demethylating agent.

13. The method of claim 12, wherein the demethylating agent is a DNA (cytosine-5)-methyltransferase 1 (DNMT1) inhibitor.

14. The method of claim 12, wherein the demethylating agent is a cytidine analog.

15. The method of claim 14, wherein the demethylating agent is agent is 5-azacytidine, 5-aza-2-deoxycytidine.

16. The method of claim 12, wherein the demethylating agent is agent is zebularine.

17. The method of claim 12, wherein the agent is a vector comprising a nucleic acid sequence encoding a gene or portion thereof.

18. The method of claim 12, wherein the agent is a polynucleotide, polypeptide, or small molecule.

19-21. -21. (canceled)

22. A method of inducing myeloid differentiation of a progenitor cell, comprising contacting a progenitor cell with a demethylating agent, thereby inducing myeloid differentiation of the progenitor cell.

23. The method of claim 22, wherein the demethylating agent is a DNA (cytosine-5)-methytransferase 1 (DNMT1) inhibitor.

24. The method of claim 22, wherein the demethylating agent is a cytidine analog.

25. The method of claim 24, wherein the demethylating agent is agent is 5-azacytidine, 5-aza-2-deoxycytidine.

26. The method of claim 22, wherein the demethylating agent is agent is zebularine.

27. The method of claim 22, wherein the progenitor cell is a multipotent progenitor (MPP), a common lymphoid progenitor (CLP), or athymic T cell progenitor.

28. (canceled)

29. A method of differentiating a progenitor cell comprising contacting a progenitor cell with an agent that alters regulation of the expression or expression product of a gene known to be associated with the differentiation potential of the cell, thereby differentiating the progenitor cell.

30. The method of claim 29, wherein the agent alters regulation of the expression or expression product of a gene set forth in Tables 2a to 2h, Tables 3a to 3h, FIGS. 1, 3, 5, 8, 9, 10 and any combination thereof.

31. The method of claim 29, wherein the agent is a demethylating agent.

32. The method of claim 31, wherein the demethylating agent is a DNA (cytosine-5)-methyltransferase 1 (DNMT1) inhibitor.

33. The method of claim 31, wherein the demethylating agent is a cytidine analog.

34. The method of claim 33, wherein the demethylating agent is agent is 5-azacytidine 5-aza-2-deoxycytidine.

35. The method of claim 31, wherein the demethylating agent is agent is zebularine.

36. The method of claim 29, wherein the agent is a vector comprising a nucleic acid sequence encoding a gene or portion thereof.

37. The method of claim 29, wherein the agent is a polynucleotide, polypeptide, or small molecule.

41. The method of claim 29, wherein expression of at least one of Meis1, Prdm16, 2900052L18Rik, Hlf, Hoxa9, or Hoxa6, is decreases as compared to expression before contacting the cell with the agent.

38-40. -40. (canceled)

42-45. -45. (canceled)

46. A method of characterizing the methylation status of the nucleic acid of a cell, comprising:

hybridizing labeled and digested nucleic acid of a cell to a DNA microarray comprising at least 2000 nucleic acid sequences;

determining a pattern of methylation from the hybridizing of (a), thereby characterizing the methylation status for the cell,

wherein the one or more nucleic acid sequences are selected from the Tables 2a to 2h, Tables 3a to 3h, FIGS. 1, 3, 5, 8, 9, 10 and any combination thereof.

47. The method of claim 46, further comprising comparing the methylation status profile to a methylation profile from hybridization of the microarray with labeled and digested nucleic acid from a progenitor cell.

48. The method of claim 47, wherein the progenitor cell is a multipotent progenitor (MPP), a common lymphoid progenitor (CLP), or a thymic T cell progenitor.

50. The method of claim 46, further comprising performing one or more techniques selected from the group consisting of a nucleic acid amplification, polymerase chain reaction (PCR), methylation specific PCR, bisulfite pyrosequencing, single-strand conformation polymorphism (SSCP) analysis, and restriction analysis.

49. (canceled)

51. A plurality of nucleic acid sequences, selected from the group consisting of the differentially methylated region (DMR) sequences as set forth in Tables 2a to 2h, FIGS. 1, 3, 5, 8, 9, 10, and any combination thereof.

52. The plurality of nucleic acid sequences of claim 51, wherein the plurality is a microarray.

53-54. -54. (canceled)